A Drug & Medical Device Recall And/Or Safety Alert Has Been Issued: Nulojix (belatacept): Risk Evaluation and Mitigation Strategy (REMS). According to the Food & Drug Administration FDA’s MedWatch:
Increased Risk of Post-transplant Lymphoproliferative Disorder (PTLD) and Progressive Multifocal Leukoencephalopathy (PML).
For more information on the drug or medical device recall or safety alert, read the Food & Drug Administration’s FDA’s drug or medical device recall or safety alert: Nulojix (belatacept): Risk Evaluation and Mitigation Strategy (REMS).
To report an adverse reaction, problem or other issue with a drug or medical device, submit a drug or medical device complaint to the government at fda.gov or MedWatch.
If you have thoughts on the drug or medical device recall or safety alert, share your drug or medical device recall or safety alert comments below.